Strategic Diagnostics and Fred Hutchinson Ink Biomarker Discovery Pact | GenomeWeb

NEW YORK (GenomeWeb News) – Strategic Diagnostics and the Fred Hutchinson Cancer Center said yesterday that they will collaborate to discover biomarkers for use in the early detection of a variety of cancers.

Under the collaboration, which will initially focus on pancreatic cancer, Newark, NJ-based SDI will provide approximately 1,000 of its cancer antigen antibodies to Paul Lampe, full member and associate program head of the Molecular Diagnostics Program at Seattle's Hutchinson Center.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: Neanderthal-derived DNA linked to modern ailments, and more.

Japan needs to catch up on its gene-editing research efforts, the Japan News writes.

Hundreds of people have signed an online petition calling for zero tolerance to sexual harassment in the sciences.

Jeff Huber, former Google X senior vice president, joins Grail as its CEO.

Mar
03
Sponsored by
Agilent Technologies

This webinar will discuss the use of a hybrid capture-based FFPE DNA sequencing methodology with the potential for advancing precision oncology studies.